Literature DB >> 34187273

Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery.

Xianyin Lai1, Jason Tang1, Mohamed E H ElSayed1.   

Abstract

Introduction: To discover and develop a peptide, protein, or antibody into a drug requires overcoming multiple challenges to obtain desired properties. Proteolytic stability is one of the challenges and deserves a focused investigation.Areas covered: This review concentrates on improving proteolytic stability by engineering the amino acids around the cleavage sites of a liable peptide, protein, or antibody. Peptidases are discussed on three levels including all peptidases in databases, mixtures based on organ and tissue types, and individual peptidases. The technique to identify cleavage sites is spotlighted on mass spectrometry-based approaches such as MALDI-TOF and LC-MS. For sequence engineering, the replacements that have been commonly applied with a higher chance of success are highlighted at the beginning, while the rarely used and more complicated replacements are discussed later. Although a one-size-fits-all approach does not exist to apply to different projects, this review provides a 3-step strategy for effectively and efficiently conducting the proteolytic stability experiments to achieve the eventual goal of improving the stability by engineering the molecule itself.Expert opinion: Improving the proteolytic stability is a spiraling up process sequenced by testing and engineering. There are many ways to engineer amino acids, but the choice must consider the cost and properties affected by the changes of the amino acids.

Entities:  

Keywords:  Proteolytic stability; amino acid replacement; antibody; cleavage site; peptidase; peptide; protein

Mesh:

Substances:

Year:  2021        PMID: 34187273     DOI: 10.1080/17460441.2021.1942837

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  2 in total

1.  nurP28, a New-to-Nature Zein-Derived Peptide, Enhances the Therapeutic Effect of Docetaxel in Breast Cancer Monolayers and Spheroids.

Authors:  Plinio Alejandro Trinidad-Calderón; Laura Margarita López-Castillo; Salvador Gallegos-Martínez; Grissel Trujillo-de Santiago; Silverio García-Lara; Mario Moisés Álvarez
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

2.  Lipocalin-2 is an essential component of the innate immune response to Acinetobacter baumannii infection.

Authors:  Jessica R Sheldon; Lauren E Himmel; Dillon E Kunkle; Andrew J Monteith; K Nichole Maloney; Eric P Skaar
Journal:  PLoS Pathog       Date:  2022-09-02       Impact factor: 7.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.